Business Wire

FLUENCE

12.5.2022 14:02:09 CEST | Business Wire | Press release

Share
Belgian Grower Tomerel Increases Light Levels, Decreases Energy Costs Through Fluence LED Retrofit

Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its partnership with Tomerel, a tomato grower located in Antwerp, Belgium. Together, the companies retrofitted half of Tomerel’s glasshouse from high-pressure sodium (HPS) fixtures to LEDs, resulting in a 40% increase in light levels while decreasing energy input by 5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005116/en/

Tomerel is a multi-generational family farm led by CEO and co-owner Jelle de Ryck—son of founders Els and Eric. Tomerel specializes in glasshouse-grown tomatoes, with a particular focus on cherry tomatoes on the vine. Like many growers in the region, Jelle de Ryck scaled his family’s facility using supplemental HPS fixtures. However, when Jelle sought to maximize the glasshouse’s light output and energy consumption, he turned to Fluence’s advanced LED technology.

“When we set out to identify a partner to assist with our lighting retrofit, we weren’t just looking for lights—we wanted a team that could strategize with us from installation through harvesting. Fluence provided that service and more,” said Jelle.

After installing Fluence’s VYPR 3p top light solution, what were once critical limitations to the farm’s lighting strategy became opportunities to boost yields and reduce energy costs. Traditional HPS fixtures produce excess heat and feature inflexible spectral options. Fluence LEDs, however, run cooler and use a more efficient spectrum. With exploding energy prices in the region, the lightened load on the glasshouse’s HVAC system, in combination with the LEDs’ overall more efficient energy usage, enabled Tomerel to cut its electricity usage while increasing light levels.

“Fluence’s technology drove success for us in multiple ways. The electricity efficiencies enabled us to sell 25% more energy back to the grid and also reduced our gas consumption by 5%. The plants are also thriving under LEDs. We’re seeing improved quality and production throughout the winter months, increases in stem density and improved translocation of sugars throughout the night,” Jelle added.

In close coordination with Fluence’s technical team, Tomerel implemented a PhysioSpec™ DUAL R9B spectral strategy to accommodate plant efficacy. This strategy enabled Tomerel to decrease energy input by 5% even while increasing the amount of light by 40%, ensuring stronger cultivation conditions for Tomerel’s tomato crop. As a result, Tomerel also increased its yield by more than 5% despite the facility receiving 5% less natural light over the winter season. Tomerel also saw an increase in overall fruit weight following the retrofit.

“It is fascinating to see growers like Tomerel make innovative, smart cultivation decisions regarding energy usage,” said Timo Bongartz, general manager for Europe, the Middle East and Africa for Fluence. “The Tomerel team is saving energy wherever possible and also optimizing their facility in such a way to enable them to sell energy back to the grid. And all that without sacrificing plant quality. Fluence is delighted to support Tomerel in running a future-proof glasshouse.”

With Fluence’s technology, the Tomerel team sold 25% more of the glasshouse’s electricity produced by co-generation back to the grid during peak energy prices and saved 5% of its total gas consumption.

For more information on Fluence, visit www.fluence.science .

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye